Amyloid-β in Alzheimer's disease: the horse or the cart? Pathogenic or protective?

Authors


Mark A. Smith, PhD
Institute of Pathology
Case Western Reserve University
2085 Adelbert Road
Cleveland
OH 44106
USA
Tel.: +1 216 368 3670
Fax: +1 216 368 8964
E-mail: mark.smith@case.edu

Summary

While the pathogenesis of Alzheimer's disease (AD) is unclear, amyloid-β plaques remain major lesions in the brain of individuals with AD. Likewise, amyloid-β is one of the best-studied proteins relating to the pathogenesis of AD. Indeed, the pathological diagnosis of AD tends to be congruous with the quantity of amyloid-β. However, it is important to recognize that pathological diagnosis merely represents the association of a pattern of pathological changes with a clinical phenotype. Therefore, it should be acknowledged that, although amyloid-β detection and semiquantification have some diagnostic utility, the simple presence of amyloid plaques, as with proteinaceous accumulations in essentially all neurodegenerative diseases, does not presume aetiology. Thus, in this review, we discuss the role of amyloid-β in the pathogenesis of AD and provide an alternative view to the widely accepted dogma.

Ancillary